Pyxis Oncology (PYXS) to Release Earnings on Wednesday

Key Points

• Pyxis Oncology is set to announce its Q2 2025 earnings on August 13, with analysts expecting a loss of ($0.36) per share.
• The company's shares have experienced a price range between $0.83 and $5.39 over the past year, with a current market cap of $66.91 million.
• HC Wainwright maintains a buy rating for Pyxis Oncology, setting a target price of $5.00, while the consensus rating is a Moderate Buy with a target price of $9.00.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06). On average, analysts expect Pyxis Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock traded down $0.01 during trading on Friday, reaching $1.06. The company's stock had a trading volume of 379,719 shares, compared to its average volume of 357,285. The stock has a 50-day moving average price of $1.18 and a two-hundred day moving average price of $1.18. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Pyxis Oncology in a report on Monday, May 19th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $9.00.

Institutional Trading of Pyxis Oncology

An institutional investor recently bought a new position in Pyxis Oncology stock. Acadian Asset Management LLC bought a new position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 84,122 shares of the company's stock, valued at approximately $81,000. Acadian Asset Management LLC owned 0.14% of Pyxis Oncology at the end of the most recent quarter. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.